Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch

Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)

Related Keywords

,Jules Abraham ,Auxilium Pharmaceuticals ,Nasdaq ,Securities Exchange ,Petros Pharmaceuticals ,Endo Pharmaceuticals ,Petros Pharmaceuticals Inc ,Exchange Commission ,Drug Administration ,Formative Human Factors ,Web App ,Human Factors Study ,Fady Boctor ,Petro President ,Chief Commercial ,Drug Facts Label ,Label Comprehension Studies ,Self Selection Studies ,Actual Use Trial ,Additional Conditions ,Nonprescription Use ,Safety Information ,Non Arteritic Ischemic Optic Neuropathy ,Erectile Dysfunction Therapies ,Prescribing Information ,Securities Act ,Securities Exchange Act ,Nasdaq Stock Market ,Financial Condition ,Ihr Portfolio ,